Ezetimibe
| 證據等級: L5 | 預測適應症: 4 個 |
目錄
Ezetimibe: From Hypercholesterolemia to Hyperlipoproteinemia
One-Sentence Summary
Ezetimibe is a cholesterol-absorption inhibitor whose established clinical use is lowering LDL-cholesterol in hypercholesterolemia and mixed dyslipidemia, typically as an add-on to statin therapy. The TxGNN model predicts it may be effective for Hyperlipoproteinemia, with 50 clinical trials and 19 publications currently supporting this direction. ⚠️ Note: this evidence pack itself flags a data-quality issue — see "Why is This Prediction Reasonable?" below.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in this dataset (licenses list is empty) — clinically known as hypercholesterolemia/dyslipidemia; treated as a blocking data gap (DG001), not a true "no original indication" |
| Predicted New Indication | Hyperlipoproteinemia |
| TxGNN Prediction Score | 99.63% |
| Evidence Level | L1 |
| Germany Market Status | ✗ Not marketed (per this dataset — see data-quality note below) |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Ezetimibe inhibits the intestinal Niemann-Pick C1-Like 1 (NPC1L1) transporter, reducing dietary and biliary cholesterol absorption in the small intestine. This lowers the delivery of cholesterol to the liver, upregulates hepatic LDL receptor expression, and produces a clinically meaningful reduction in LDL-cholesterol, typically used in combination with statins for an additive lowering effect.
Hyperlipoproteinemia is a broad umbrella term encompassing elevated LDL-C/mixed lipid disorders — mechanistically and clinically this overlaps directly with ezetimibe's already-established use in hypercholesterolemia and mixed hyperlipidemia (as reflected in dozens of completed Phase 3 trials, including combinations with fenofibrate, statins, bempedoic acid, and obicetrapib).
Data-quality caveat: The evidence pack's own repurposing_rationale explicitly flags an internal inconsistency: this dataset records market_status = "未上市" (not marketed) and an empty original_indications list, which contradicts the well-known fact that ezetimibe (Zetia®/Ezetrol®) is a globally approved lipid-lowering agent. The evidence pack itself concludes this is not a genuine drug-repurposing candidate, but rather a case of missing/incomplete regulatory source data (BfArM label not yet ingested — DG001, Blocking) combined with a missing MOA field (DG002, High). The clinical trial and literature evidence below is real and substantial, but it largely supports an already-recognized indication rather than a novel repositioning hypothesis. This must be resolved before any downstream decision is finalized.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT03884452 | Phase 3 | Completed | 50 | Ezetimibe 10 mg + atorvastatin/simvastatin in homozygous familial hypercholesterolemia |
| NCT00092573 | Phase 3 | Completed | 576 | Fenofibrate + ezetimibe coadministration in mixed hyperlipidemia |
| NCT00652431 | Phase 1 | Completed | 18 | PK interaction study: Vytorin (ezetimibe/simvastatin) + Niaspan (niacin ER) |
| NCT04929249 | Phase 3 | Completed | 450 | "Inclisiran first" strategy vs usual care in ASCVD with elevated LDL-C on maximal statin ± ezetimibe |
| NCT05255094 | Phase 3 | Completed | 464 | AK102 (PCSK9 inhibitor) in primary hypercholesterolemia/mixed hyperlipidemia; ezetimibe-relevant population overlap |
| NCT00552097 (ENHANCE) | Phase 3 | Completed | 720 | Ezetimibe + high-dose simvastatin vs simvastatin alone on carotid atherosclerosis progression in heterozygous FH |
| NCT03337308 | Phase 3 | Completed | 382 | Bempedoic acid 180mg + ezetimibe 10mg FDC vs components/placebo on top of maximal statin therapy |
| NCT06005597 | Phase 3 | Completed | 407 | Obicetrapib 10mg + ezetimibe 10mg FDC in HeFH and/or ASCVD/high-risk patients |
| NCT02748057 | Phase 3 | Completed | 135 | Long-term safety/tolerability of ezetimibe + rosuvastatin FDC in Japanese hypercholesterolemia patients |
| NCT01043380 (PRECISE-IVUS) | Phase 4 | Completed | 245 | IVUS-measured coronary plaque regression: cholesterol absorption inhibitor (ezetimibe) vs synthesis inhibitor |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 40347969 | 2025 | RCT | Lancet | TANDEM trial: obicetrapib + ezetimibe FDC significantly reduces LDL-C |
| 41206969 | 2026 | RCT | JAMA | Oral PCSK9 inhibitor enlicitide in HeFH patients not achieving LDL-C goals on existing therapy incl. ezetimibe |
| 18376001 | 2008 | Editorial/Commentary | N Engl J Med | Editorial on cholesterol lowering and ezetimibe (ENHANCE trial controversy) |
| 19654419 | 2009 | Review | Drug and Therapeutics Bulletin | Ezetimibe update: efficacy/safety review, no proven CV mortality/morbidity benefit at time of writing |
| 25939291 | 2015 | Review | Cardiology Clinics | Familial hypercholesterolemia treatment overview including statins, ezetimibe, and other LDL-lowering agents |
| 38599725 | 2024 | Review | Indian Heart Journal | FH epidemiology, underdiagnosis, and treatment landscape |
| 37762244 | 2023 | Review | Int J Mol Sci | Postprandial hyperlipidemia pathophysiology, diagnosis, and treatment |
| 33766264 | 2021 | Review | J Am Coll Cardiol | Emerging LDL-C/ApoB-lowering therapies incl. ezetimibe-based combinations |
| 35593194 | 2022 | Review | J Cardiovasc Pharmacol Ther | Comprehensive review of PCSK9 inhibitors, statin-intolerant/FH populations |
| 30702994 | 2019 | Review | Circulation Research | Overview of cholesterol-lowering agent classes including ezetimibe |
Germany Market Information
No BfArM authorization records are present in this evidence pack (total_licenses = 0, licenses = []). This is inconsistent with ezetimibe's known long-standing market presence in Germany/EU (e.g., Ezetrol®, Inegy®/Vytorin® combination products) and has been logged as data gap DG001 (Blocking) — the regulatory label/authorization data has not yet been ingested from the BfArM source. This gap must be closed before any safety or authorization claims can be made about this candidate.
Safety Considerations
Please refer to the package insert for safety information. (All safety fields in this dataset — key warnings, contraindications, and drug interactions — are currently unavailable; DDI query returned no results.)
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The clinical trial and literature base for ezetimibe in LDL-C/hyperlipoproteinemia-type indications is extensive and high-quality (L1 evidence, multiple completed Phase 3 RCTs including the pivotal ENHANCE trial and modern FDC studies). However, this dataset's own regulatory and MOA fields are incomplete and internally inconsistent with ezetimibe's known real-world approval status, so this should be treated as evidence consolidation for a plausible/likely-already-approved use rather than a validated novel repurposing signal until the data gaps are resolved.
To proceed, the following is needed:
- Resolve DG001 (Blocking): retrieve and parse the actual BfArM/TFDA label PDF to confirm true market status, licenses, and approved indication text
- Resolve DG002 (High): query DrugBank API for confirmed MOA to replace the current placeholder
- Reconcile the
market_status = "未上市"/ emptyoriginal_indicationsfields against ezetimibe's known approved indications, to determine whether "Hyperlipoproteinemia" is a genuinely new label extension or an existing on-label use - Obtain safety/contraindication data (key warnings, DDI) once the label source is available
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.